Somaxon Pharmaceuticals (SOMX) Posts Q4 Loss of 21c/Share, Inline with the Street

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q4 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.42 million.

Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.

For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• RegenLab targets Nasdaq listing under ticker RGNA as revenues top $29 million
• BMS Zenbexus doubles response rates in myeloma trial